Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services

/in , , , , /by

Lantern Pharma a clinical stage oncology biotech leveraging A.I. and machine learning genomics company has selected REPROCELL Inc. to provide drug screening and drug sensitivity services. BELTSVILLE, MD.: REPROCELL Inc. a stem cell and drug discovery company has announced today that they have been selected by Lantern Pharma to provided preclinical screening and drug sensitivity for its portfolio of oncology drugs. The collaboration […]

Read more →

BioLife Solutions Acquires Custom Biogenic Systems

/in , , , , /by

Global leader in liquid nitrogen storage systems expected to support growth, diversify revenue and reduce evo® manufacturing costs Preliminary 2020 revenue guidance of $50 – $56 Million Conference call begins today at 4:30 p.m. Eastern time BOTHELL, Wash. — BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of best-in-class […]

Read more →

Takara Bio Announces Launch of Human iPSC-derived Intestinal Epithelial Cells for Drug Discovery Research

/in , /by

MOUNTAIN VIEW, Calif.–Takara Bio USA, Inc. (TBUSA) announced that its parent company, Takara Bio Inc., has launched the world’s first commercially available small intestinal epithelial cells derived from human induced pluripotent stem cells. The new Cellartis® Intestinal Epithelial Cells (from ChiPSC18) Kit was jointly developed when Takara Bio received a technology transfer from a differentiation induction method […]

Read more →

Immatics Implements Genedata Biologics into Proprietary T-Cell Receptor Discovery and Engineering XCEPTOR Platform

/in , , , , /by

Leading immuno-oncology company adopts Genedata Biologics to support the discovery and development of TCRs for adoptive cell therapies and bispecific TCR molecules Basel, Switzerland Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies, a clinical-stage biopharmaceutical company developing T-cell receptor (TCR)-based cancer immunotherapies, has adopted Genedata Biologics® to streamline their R&D […]

Read more →

Gemini Bio Announces the Acquisition of ORFLO Technologies

/in , /by

* ORFLO’s cell analysis offering to complement Gemini’s portfolio of cell culture reagents WEST SACRAMENTO, CA – Gemini Bioproducts, LLC (“Gemini”), a leading provider of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the acquisition of ORFLO Technologies (“ORFLO”), an innovative life sciences instrumentation company. Founded in 2003 […]

Read more →

prismCDX Implements Ultivue’s UltiMapper™ Platform for Standardized, Comprehensive Cancer Tissue Phenotypic Characterization

/in , /by

SEOUL, South Korea–prismCDX, a highly specialized contract research organization announced today the selection and adoption of the UltiMapper platform to broaden its offering of translational biomedical research services. The addition of Ultivue’s highly standardized multiplex tissue marker assays enables the identification of critical cellular phenotypes and tissue marker signatures in support of translational and clinical […]

Read more →

Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services

/in , /by

Kassel, Germany and Cambridge, MA – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs. UltiMapper multiplex immuno-histochemistry […]

Read more →

Genedata Expands Partnership with Boehringer Ingelheim to Digitalize Next Generation Cell Line Development

/in , , , /by

Genedata Selector® deployed to streamline complex cell line development processes Basel, Switzerland – Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced an expansion of its collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company, to digitalize and automate complex cell line development processes. As part of this collaboration, Genedata Selector has been deployed […]

Read more →

Technology brings university scientists unparalleled potential for chemical, biological and human disease research First commercial research instrument of its kind in the world. MILFORD, Mass.–(BUSINESS WIRE)– Aston University and Waters Corporation (NYSE: WAT) announced today the completed installation of the world’s first Waters™ SELECT SERIES™ Cyclic™ IMS (ion mobility spectrometry) mass spectrometer within the University’s School of Health and Life Sciences, where the instrument will support research into the biology of human diseases, the discovery of new therapeutics and advances in biotechnology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005188/en/ Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Mass spectrometry (MS) is a widely deployed analytical method used by scientists to identify and quantify molecules in a sample and determine their detailed molecular structure. For example, it can be used to more effectively identify disease biomarkers that allow for early detection. Ion mobility spectrometry is a proven technique that separates ions by their size, shape and charge. The SELECT SERIES Cyclic IMS takes ion mobility to a new level, replacing the traditional linear ion mobility region with a novel compact cyclic device. Ions traverse around the cyclic region and with every pass greater ion mobility resolution is achieved. In addition, the advanced technology enables the unique ability to perform ion mobility selection for ion mobility/ion mobility and IMSn experiments. The new instrument will be used by researchers at Aston University and across the Midland Innovation consortium to answer complex biological questions. Andrew Pitt, Professor of Pharmaceutical Chemistry & Chemical Biology, Aston University said: “We are delighted to have this new technology in our lab here at Aston; it will provide us and other researchers in the Midlands with a step change in how we conduct our research. “The new instrument is one of a relatively recent class of mass spectrometers, incorporating ion mobility, which separate molecules based not only on their mass but also by their shape. This allows us to see what is going on in biology in much more detail, including information we are able to gain from the shape of molecules that will allow us to solve much more complex questions.” Combining novel IMS capability with significantly improved mass spectrometry performance and enabling software, this platform allows leading researchers to unlock the potential in scientific discovery. Jim Langridge, Advanced MS Technologies Waters Corporation said: “Human biology is extraordinarily complex and the SELECT SERIES Cyclic IMS gives research scientists the ability to probe deeper into the chemistry and biology of human disease like never before. “By collaborating with leading researchers like Professor Pitt, we continually advance the science of mass spectrometry, accelerating their research into human health and well-being.” Aston University scientists will run a visiting researcher programme that will allow researchers from many disciplines to visit Aston and work with the first-of-its-kind SELECT SERIES Cyclic IMS instrument, exploring its unparalleled experimental potential. The journal Analytical Chemistry documented the effectiveness and power of the cyclic IMS instrument in a recent article titled: A Cyclic Ion Mobility – Mass Spectrometry System. About Aston University Founded in 1895 and a University since 1966, Aston is a long established university led by its three main beneficiaries – students, business and the professions, and our region and society. Aston University is located in Birmingham and at the heart of a vibrant city and the campus houses all the university’s academic, social and accommodation facilities for our students. Professor Alec Cameron is the Vice Chancellor & Chief Executive. About Waters Corporation Waters Corporation (NYSE: WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. Waters and SELECT SERIES are trademarks of Waters Corporation.

/in , , , /by

Cambridge, UK – Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls. Acquiring reliable off-the-shelf knockout mouse models or cell lines that match specific experimental requirements can be challenging, and often need to be sourced directly from individual researchers or labs. Abcam’s newly-launched collection addresses this issue by providing access to […]

Read more →

Cells that could lead to new therapies: PromoCell now offers in vitro disease models

/in , , , /by

Portfolio extension: Wide range of donor cells with common chronic diseases New models can help researchers investigate disease development and find new treatment approaches Matched growth media are optimized for pharmaceutical drug discovery Heidelberg, Germany – PromoCell, a premier manufacturer of human primary cells and cell culture products, now offers cell disease models covering a […]

Read more →